Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106282 · ClinicalTrials.gov registry record
Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 105
- Enrollment target
NCT06106282: Completed study, sponsored by Mayo Clinic.
NCT06106282 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06106282 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).
Interventions
- OTHER Non-Interventional Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2023-07-12 |
| Est. Completion | 2025-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106282
The ClinicalTrials.gov registry entry for NCT06106282 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06106282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06106282 about?
NCT06106282 is a clinical study titled "Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)". This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).
What is the current status of trial NCT06106282?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2023-07-12. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT06106282?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06106282?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.